Physician profile
Elizabeth Mccabe
NPI 1366888604
$1,499.98
in general payments reported to CMS, 2019-2025
30 companies · $214 in 2025
The $214 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.36 · 2020: $49.05 · 2021: $388 · 2022: $313 · 2023: $332 · 2024: $120 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $216.62 | 2019-2022 | |
| Corium, LLC | $175.33 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $137.47 | 2021-2024 | Qelbree |
| Novo Nordisk INC | $124.54 | 2019-2025 | Ozempic |
| Amgen INC. | $82.55 | 2019-2023 | Prolia, Evenity |
| Eisai INC. | $55.37 | 2020-2021 | |
| Amarin Pharma, INC. | $48.91 | 2021 | |
| Nestle Healthcare Nutrition INC. | $47.87 | 2021-2023 | |
| Glaxosmithkline, LLC. | $46.24 | 2022-2023 | Shingrix |
| Abbvie INC. | $46.09 | 2023-2024 | |
| Tris Pharma INC | $44.68 | 2023 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $40.92 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $37.95 | 2024 | |
| Hologic Sales and Service, LLC | $36.40 | 2022-2024 | Thinprep 2000 Processor, Aptima |
| Biomarin Pharmaceutical INC. | $36.33 | 2023-2025 | Voxzogo 1.2mg |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.31 | 2025 | |
| Sanofi Pasteur INC. | $34.74 | 2025 | |
| Merck Sharp & Dohme LLC | $32.15 | 2023 | Vaxneuvance, M-M-R II, Gardasil 9 |
| Dexcom, INC. | $31.84 | 2023-2025 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $24.24 | 2021-2024 | Heplisav-B |
| Antares Pharma, INC. | $18.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.22 | 2023 | Xifaxan |
| Ultragenyx Pharmaceutical INC. | $17.64 | 2022 | |
| Genentech USA, INC. | $17.49 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.88 | 2021 | |
| Abbott Laboratories | $16.78 | 2025 | Freestyle Libre 3 |
| Shire North American Group INC | $16.55 | 2019 | |
| Mylan Specialty L.P. | $14.19 | 2023 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $13.67 | 2022 | |
| Kaleo, INC. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.